A tool for predicting the thermal performance of a diesel engine

This paper presents a thermal network model for the simulation of the transient response of diesel engines. The model was adjusted by using experimental data from a completely instrumented engine run under steady-state and transient conditions. Comparisons between measured and predicted material temperatures over a wide range of engine running conditions show a mean error of 7◦C. The model was then used to predict the thermal behavior of a different engine. Model results were checked against oil and coolant temperatures measured during engine warm-up at constant speed and load, and on a New European Driving Cycle. Results show that the model predicts these temperatures with a maximum error of 3◦C.Torregrosa, AJ.; Olmeda González, PC.; Martín Díaz, J.; Romero Piedrahita, CA. (2011). A tool for predicting the thermal performance of a diesel engine. Heat Transfer Engineering. 32(10):891-904. doi:10.1080/01457632.2011.548639S891904321

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

CFD Investigation of the Effects of Split Main Fuel Injection Parameters on Combustion and Emissions in a Light-Duty Diesel Engine

The paper outlines CFD investigations on the combustion and emission effects of the fuel injection strategies in a direct injection diesel engine fitted with a high pressure common rail fuel injection system. Strategies using a split main injection has been explored, with the variables of interest including the ratio of the first to second part of the main, the separation between these and the timing of the start of main injection. Exhaust gas recirculation rate was a fourth variable. The main influence of these 4 parameters on the nature of the combustion, and the resulting NO and soot emissions is characterised. Model validation has been based on comparisons with experimental data for heat release rate and engine-out emissions values. Simulations have been performed under typical part-load operating conditions, where the temporal and spatial developments of combustion/emissions processes are mapped out

Running real-time engine model simulation with hardware-in-the-loop for diesel engine development

The paper reports the design of a model and HIL system produced to support the development and testing of Electronic Control Unit/Engine Management System (ECU/EMS) software for a V6 turbo-charged automotive diesel engine. The engine model, developed in Simulink, is compiled to execute on a dSpace platform and interacts with the ECU/EMS module in real time. The main features of the engine model are outlined. The configuration of the model and HIL components are described, and the performance of the system is illustrated and discussed. Practical decisions on the inclusion of real or virtual sensors and actuators, and other implementation issues, are explained. Recent and potential future applications of the system are described